Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 11/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21682109 | 1.00 | PRMT5 (0.39) | PRMT5WDR77SLC22A12FGFR1FGFR4 | |
| SCHEMBL21682231 | 0.77 | PRMT5 (0.36) | PRMT5WDR77SLC22A12FGFR1FGFR4 | |
| SCHEMBL21682232 | 0.77 | PRMT5 (0.36) | PRMT5WDR77SLC22A12FGFR1FGFR4 | |
| SCHEMBL21682165 | 0.77 | PRMT5 (0.36) | PRMT5WDR77SLC22A12FGFR1FGFR4 | |
| SCHEMBL21682166 | 0.77 | PRMT5 (0.36) | PRMT5WDR77SLC22A12FGFR1FGFR4 | |
| SCHEMBL16769943 | 0.77 | SLC22A12 (0.40) | PRMT5WDR77SLC22A12FGFR1FGFR4 | |
| SCHEMBL30897072 | 0.77 | PDE4A (0.39) | FGFR1FGFR4 | |
| SCHEMBL30897077 | 0.77 | PDE4A (0.39) | FGFR1FGFR4 | |
| SCHEMBL23692929 | 0.74 | PRMT5 (0.42) | PRMT5WDR77SLC22A12NNMT | |
| SCHEMBL31123772 | 0.74 | PRMT5 (0.42) | PRMT5WDR77SLC22A12NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| CN-112805006-B | PRMT5 inhibitors | 默沙东有限责任公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3833355-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020033288-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363707-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 159/4885SLC22A12 2064/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 159/4885SLC22A12 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.